Dermatomyositis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Dermatomyositis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 18
17:30 2023
Dermatomyositis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Dermatomyositis Pipeline Insights
United States, Nevada, Las Vegas, DelveInsight’s ‘Dermatomyositis Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Dermatomyositis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dermatomyositis pipeline domain.

United States, Nevada, Las Vegas, DelveInsight’s Dermatomyositis Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Dermatomyositis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dermatomyositis pipeline domain.

Key Takeaways from the Dermatomyositis Pipeline Report

  • Over 10+ Dermatomyositis pipeline therapies are in various stages of development, and their anticipated acceptance in the Dermatomyositis market would significantly increase market revenue. 
  • Leading Dermatomyositis companies developing novel drug candidates to improve the Dermatomyositis treatment landscape include Corbus Pharmaceuticals, Kezar Life Sciences, and others.
  • Promising Dermatomyositis pipeline therapies in various stages of development include Lenabasum, KZR-616, and others.

Dermatomyositis Overview

Dermatomyositis is a type of inflammatory myopathy characterized by inflammatory and degenerative changes of the muscles and skin. Associated symptoms and physical findings may vary widely from case to case as patients may present differently. Muscle abnormalities may begin with aches and weakness of the muscles of the trunk, upper arms, hips, and thighs (proximal muscles). Muscles may be stiff, sore, tender and, eventually, show signs of degeneration (atrophy). Dermatomyositis may be diagnosed based upon a detailed patient history, thorough clinical examination, detection of characteristic physical findings, and certain specialized tests. Glucocorticoids, particularly prednisone, are widely used in treating dermatomyositis and are often used first-line. High dose glucocorticoid therapy may produce adverse side effects, particularly after prolonged use, such as a decrease in bone density, causing bones to become brittle and weakened (osteoporosis); increasing, “superimposed” muscle weakness due to effects of the medication (i.e., corticosteroid myopathy); tissue swelling (edema); peptic ulcers; elevated blood pressure; elevated blood sugar levels; weight gain with fat deposits in the abdomen, face, and/or back of the neck or other findings.

Dermatomyositis Pipeline Analysis: Drug Profile

Lenabasum: Corbus Pharmaceuticals

Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has an acceptable safety and tolerability profiles without evidence of immunosuppression. Lenabasum is currently in phase III stage of development to treat Dermatomyositis. 

Discover more about the emerging Dermatomyositis drugs @ Dermatomyositis Treatment Drugs

Dermatomyositis Key Companies

  • Corbus Pharmaceuticals
  • Kezar Life Sciences

Dermatomyositis Pipeline Therapies

  • Lenabasum
  • KZR-616

Dermatomyositis Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Dermatomyositis Pipeline Report 

  • Coverage: Global 
  • Key Dermatomyositis Companies: Corbus Pharmaceuticals, Kezar Life Sciences, and others
  • Key Dermatomyositis Pipeline Therapies: Lenabasum, KZR-616, and others

Find out more about the Dermatomyositis treatment options in development @ Dermatomyositis Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies working in the Dermatomyositis Pipeline Segment.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/